Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423375 | 0.73 | — | — | |
| SCHEMBL3719326 | 0.71 | — | — | |
| SCHEMBL2366245 | 0.70 | POLB (0.44) | ALDH1A1L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL4268002 | 0.69 | IDH1 (0.40) | IDH1L3MBTL1GRM8GRM4MEN1 | |
| Hydrochloric Acid SCHEMBL30612668 | 0.68 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL13575346 | 0.68 | IDH1 (0.44) | IDH1ALDH1A1ESR1PADI4POLB | |
| SCHEMBL13575341 | 0.67 | KDM4E (0.50) | IDH1ESR1PADI4 | |
| SCHEMBL17583856 | 0.66 | ALDH5A1 (0.52) | ALDH1A1KMT2A | |
| SCHEMBL4147484 | 0.66 | ALDH5A1 (0.52) | ALDH1A1ESR1MEN1KMT2A | |
| SCHEMBL21459915 | 0.64 | IDH1 (0.41) | IDH1ALDH1A1ESR1PADI4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285783-B1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8263597-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2009134666-A1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | IDH1 1759/4885ALDH1A1 911/4885ESR1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.